동물용 구충제 시장 : 기회, 성장 촉진요인, 산업 동향 분석 및 예측(2025-2034년)

The Global Animal Parasiticides Market was valued at USD 12.9 billion in 2024 and is projected to grow at a CAGR of 5.3% from 2025 to 2034. This growth is fueled by the rising global animal population, increasing pet ownership, the prevalence of parasitic infections, and higher spending on animal healthcare. Contagious diseases such as intestinal parasites and tick-borne illnesses continue to pose health risks, prompting increased demand for preventive and curative treatments. Animal parasiticides, including topical solutions, oral medications, and injectables, play a crucial role in controlling infestations and safeguarding animal health. Pet owners are prioritizing parasite prevention, which has led to a surge in demand for these products in companion animals like dogs and cats. The livestock industry also relies on antiparasitic drugs to maintain animal health and sustain food production. Technological advancements in veterinary medicine, such as telemedicine platforms and point-of-care diagnostics, are also contributing to market expansion.

Animal parasiticides are categorized based on their function, with key segments including ectoparasiticides, endoparasiticides, and endectocides. The ectoparasiticides segment, which includes pour-ons, oral tablets, spot-ons, sprays, dips, ear tags, and collars, generated the highest revenue in 2024, amounting to USD 7 billion. The widespread presence of external parasites like fleas, ticks, and mites continues to drive demand for these treatments, particularly in regions with varied climates. Livestock farmers and pet owners rely on these parasiticides for effective parasite control. Innovations in formulations, including spot-on treatments and sprays, have improved adherence and efficacy, further boosting market demand. Government initiatives aimed at ensuring better animal health and hygiene also contribute to the strong market position of ectoparasiticides.

The animal parasiticides market is further segmented by type into over-the-counter (OTC) and prescription products. In 2024, the prescription segment dominated with a 74.1% market share. Prescription-based parasiticides require veterinary oversight, ensuring tailored treatment plans for animals. These products are typically more refined and specifically designed to treat targeted parasite infestations, making them more effective compared to OTC alternatives. Their potency and specificity have made them the preferred choice among veterinarians and pet owners.

Market segmentation by animal type classifies parasiticides into companion animals and farm animals. In 2024, the companion animals segment held the highest revenue share at 56.9%. The increasing number of pet adoptions and the growing awareness of parasitic disease prevention have fueled demand for these treatments. Parasites such as fleas, ticks, mites, and worms frequently affect pets, leading to various health concerns. Manufacturers continue to develop innovative solutions to meet this rising demand.

The market is further categorized by drug class, including chemical synthetic, pyrethroids, macrocyclic lactones, organophosphates, benzimidazoles, and others. The chemical synthetic segment was the largest in 2024 and is expected to grow at a CAGR of 5% over the forecast period. These parasiticides are widely used due to their broad-spectrum activity, effectiveness, and affordability. They play a vital role in both pet care and livestock management, supporting animal health and productivity.

In terms of end use, the market is divided into animal farms, veterinary hospitals and clinics, and home care settings. Veterinary hospitals and clinics accounted for the largest market share in 2024 and are projected to reach USD 12.7 billion by 2034. These facilities employ trained professionals who ensure accurate diagnosis and treatment of parasitic infections. Their role in providing prescription-based treatments, advanced diagnostics, and specialized care has solidified their dominance in the market. The growing adoption of pet insurance and higher expenditure on veterinary care also contribute to this segment's continued expansion.

Geographically, North America led the animal parasiticides market in 2024, holding a 37.2% share, and is expected to grow at a 4% CAGR over the forecast period. The increasing number of companion and livestock animals, along with strong government support for animal health initiatives, has driven demand for antiparasitic products in the region. The U.S. market alone was valued at USD 3.8 billion in 2021, grew to USD 3.9 billion in 2022, and reached USD 4.2 billion in 2023. With continuous advancements in veterinary pharmaceuticals and increasing investments in animal healthcare, the market is set to maintain its upward trajectory.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing in animal healthcare expenditure
    • 3.2.1.2 Growing trend of adoption of pet animals
    • 3.2.1.3 Rapidly increasing demand for animal protein in human food
    • 3.2.1.4 Increasing incidences of zoonotic and transboundary diseases
    • 3.2.1.5 Increasing prevalence of animal diseases
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Restrictions on parasiticide consumption in food animals
    • 3.2.2.2 High pet care cost
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pricing analysis, by product, 2024
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Ectoparasiticides
  • 5.2.1 Pour-ons and spot-ons
  • 5.2.2 Oral tablets
  • 5.2.3 Sprays
  • 5.2.4 Dips
  • 5.2.5 Ear tags
  • 5.2.6 Collars
  • 5.2.7 Other ectoparasiticides
• 5.3 Endoparasiticides
  • 5.3.1 Oral liquids
  • 5.3.2 Oral solids
  • 5.3.3 Injectables
  • 5.3.4 Feed additives
  • 5.3.5 Other endoparasiticides
• 5.4 Endectocides

Chapter 6 Market Estimates and Forecast, By Type, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Over the counter (OTC)
• 6.3 Prescription

Chapter 7 Market Estimates and Forecast, By Animal Type, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Companion animals
  • 7.2.1 Dogs
  • 7.2.2 Cats
  • 7.2.3 Horses
  • 7.2.4 Other companion animals
• 7.3 Farm animals
  • 7.3.1 Poultry
  • 7.3.2 Swine
  • 7.3.3 Cattle
  • 7.3.4 Sheep and goats
  • 7.3.5 Other farm animals

Chapter 8 Market Estimates and Forecast, By Drug Class, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Chemical synthetic
• 8.3 Macrocyclic lactones
• 8.4 Pyrethroids
• 8.5 Organophosphates
• 8.6 Benzimidazoles
• 8.7 Other drug classes

Chapter 9 Market Estimates and Forecast, By End Use, 2021 – 2034 ($ Mn)

• 9.1 Key trends
• 9.2 Veterinary hospitals and clinics
• 9.3 Animal farms
• 9.4 Home care settings

Chapter 10 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Russia
  • 10.3.7 Poland
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 Turkey

Chapter 11 Company Profiles

• 11.1 Boehringer Ingelheim International
• 11.2 Bimeda
• 11.3 Biogenesis Bagó
• 11.4 Ceva Sante Animal
• 11.5 Dechra Pharmaceuticals
• 11.6 Elanco Animal Health
• 11.7 Merck
• 11.8 Norbrook Laboratories
• 11.9 Neogen Corporation
• 11.10 Ourofino Saude Animal
• 11.11 Phibro Animal Health
• 11.12 PetIQ
• 11.13 Virbac
• 11.14 Vetoquinol
• 11.15 Zoetis